跳转至内容
Merck

N5535

Sigma-Aldrich

烟酰胺

meets USP testing specifications

别名:

烟酰胺, 吡啶-3-甲酰胺, 烟碱酰胺, 维生素 B3, 维生素 PP

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C6H6N2O
CAS号:
分子量:
122.12
Beilstein:
383619
EC號碼:
MDL號碼:
分類程式碼代碼:
12352205
PubChem物質ID:
NACRES:
NA.21

生物源

synthetic (organic)

品質等級

agency

USP/NF
meets USP testing specifications

化驗

98.5-101.5% dry basis

形狀

crystals

顏色

white

mp

128-131 °C (lit.)

應用

pharmaceutical (small molecule)

SMILES 字串

NC(=O)c1cccnc1

InChI

1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)

InChI 密鑰

DFPAKSUCGFBDDF-UHFFFAOYSA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

一般說明

烟酰胺,也称为3-吡啶甲酰胺,是水溶性维生素。在植物、动物性食品和化妆品中广泛存在。

應用

烟酰胺用于:
  • 作为胰岛成熟培养基的组分
  • 诱导胰岛素分泌细胞分化
  • 比较其与孕酮的临床前疗效

生化/生理作用

烟酰胺是烟酰胺腺嘌呤二核苷酸(NAD+)的主要前体,而NAD+是三磷酸腺苷(ATP)产生过程中的重要辅酶。 烟酰胺缺乏与糙皮病有关。
烟酰胺是维生素B3的酰胺衍生物,是PARP抑制剂

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Eye Irrit. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 1

閃點(°F)

302.0 °F - closed cup

閃點(°C)

150 °C - closed cup

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Stimulatory Role of Glycated Fetal Bovine Serum Along with Iron on In Vitro Production of Insulin by Differentiated Mouse Embryonic Stem Cells
Nishigaki I, et al.
Journal of Health Science, 57(4), 356-361 (2011)
A comparison of the effects of nicotinamide and progesterone on functional recovery of cognitive behavior following cortical contusion injury in the rat
Peterson TC, et al.
Journal of Neurotrauma, 29(18), 2823-2830 (2012)
Necrostatin-1 supplementation enhances young porcine islet maturation and in vitro function
Lau H, et al.
Xenotransplantation (2019)
Role of nicotinamide in DNA damage, mutagenesis, and DNA repair
Surjana D, et al.
Journal of Nucleic Acids, 2010 (2010)
Ann-Lii Cheng et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(32), 4067-4075 (2013-10-02)
Open-label, phase III trial evaluating whether sunitinib was superior or equivalent to sorafenib in hepatocellular cancer. Patients were stratified and randomly assigned to receive sunitinib 37.5 mg once per day or sorafenib 400 mg twice per day. Primary end point

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门